A method and device for controlling anticoagulation during blood treatment. The method includes conveying blood in a first line section, supplying biologically and/or pharmacologically active substances of negative total charge to the blood, separating the blood into corpuscular blood components and blood plasma, conveying the blood plasma in a second line section via an anion exchanger, bringing the blood plasma and corpuscular blood components together in a third line section, determining a first flow rate of blood plasma in the first line section, determining a second flow rate of blood plasma in the second line section, setting a quantity of biologically and/or pharmacologically active substances based on a ratio of the first and second flow rates such that, after the blood plasma and corpuscular blood components are brought together, a concentration of the biologically and/or pharmacologically active substances in the third line section meets a target value.

The invention provides apheresis devices and their use for removal of substantially all types of cell free DNA (cfDNA) in patients' blood, including nucleosome-bound cfDNA, exosome-bound cfDNA and unbound cfDNA (including double stranded DNA (dsDNA), single stranded DNA (ssDNA) and oligonucleotides), to limit the negative effects of the circulating cfDNA and to treat various diseases.

The invention provides apheresis devices and their use for removal of substantially all types of cell free DNA (cfDNA) in patients' blood, including nucleosome-bound cfDNA, exosome-bound cfDNA and unbound cfDNA (including double stranded DNA (dsDNA), single stranded DNA (ssDNA) and oligonucleotides), to limit the negative effects of the circulating cfDNA and to treat various diseases.

A device and method for purifying blood. The method includes the steps of separating the blood plasma from the blood cells, adjusting the pH of the blood plasma to a pH close to an isoelectric point of at least one predetermined protein, treating the blood plasma by ion-exchange chromatography, neutralizing the pH of the blood plasma, and pooling of the blood plasma and blood cells.

The present invention relates to the use of alkali hydroxide for the regeneration of apheresis columns for the affinity chromatographic removal of CRP and a method for the simplified regeneration of apheresis columns for the affinity chromatographic removal of CRP with the use of an alkali hydroxide solution and apheresis devices which are designed in such a manner as to be resistant to alkali hydroxide solutions and to allow the regeneration of apheresis columns for the affinity chromatographic removal of CRP in continuous operation.

A process for removing Hg.sup.2+ toxins from bodily fluids is disclosed. The process involves contacting the bodily fluid with a titanium metallate ion exchanger to remove the metal toxins in the bodily fluid, including blood and gastrointestinal fluid. Alternatively, blood can be contacted with a dialysis solution which is then contacted with the ion exchanger. The titanium metallate ion exchangers are represented by the following empirical formula:
A.sub.mTiNb.sub.aSi.sub.xO.sub.y. A composition is provided with the combination of the titanium metallate ion exchanger and bodily fluids or dialysis solutions. Also, provided is an apparatus comprising a matrix and the titanium metallate ion exchanger.

The device described herein converges the plasma separation function of a hollow-fiber plasmapheresis device with a formulation or cocktail of two or more adsorbent components housed in the extra-lumen space (outside the fiber walls, yet inside the outer shell of the plasmapheresis device) to optimize the adsorption of viral pathogens, shed viral proteins and viral exosomes (collectively known as the Viral Targets) in a low-shear force environment without interacting with blood cells.

The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: —the αI7I-I85cit peptide of amino acid sequence VDIDIKIX.sub.1SCX.sub.2GSCS (SEQ ID NO: 8) wherein X.sub.1 and X.sub.2 each represent a citmllyl residue, —the α62I-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citmllyl residue—the P60-74cit-NH2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citmllyl residue and X3 represents a citmllyl derivative with a carboxamide group and—the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citmllyl residue and/or the a36-50cit peptide of amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 5) wherein X.sub.1 and X.sub.2 each represent a citmllyl residue.

The present disclosure provides apparatuses and systems for delivering a measureable absorbed-dose of a gaseous activating agent to a fluid including a biological liquid and/or cells. The apparatuses or systems include a gas-fluid contact device configured to controllably rotate or oscillate a control member having an interior surface in contact with the fluid and a control system configured to control rotation or oscillation of the contact member by the gas-fluid contact device. In some embodiments, the control system is further configured to control absorption of the gaseous activating agent by the fluid. The present disclosure also provides methods of treating a fluid including a biological liquid or cells with a gaseous activating agent to controllably activate the fluid.

The present invention relates to a column comprising a vascular endothelial growth factor (VEGF) dimer molecule, a method for preparing such a column, a VEGF dimer molecule, an expression vector and a recombinant host cell encoding for a VEGF dimer, as well as uses and methods related thereto.